{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:30:01Z","timestamp":1792859401175,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.lungcan.2025.108747","type":"journal-article","created":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:28:06Z","timestamp":1757222886000},"page":"108747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer"],"prefix":"10.1016","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5917-6209","authenticated-orcid":false,"given":"Fangdi","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4789-0293","authenticated-orcid":false,"given":"Mandeep K.","family":"Banwait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4307-319X","authenticated-orcid":false,"given":"Surbhi","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2590-8262","authenticated-orcid":false,"given":"Amanda","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Piotrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila","family":"Bazhenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman T.","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8727-1886","authenticated-orcid":false,"given":"Emily W.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-980X","authenticated-orcid":false,"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3119-9334","authenticated-orcid":false,"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6678-9743","authenticated-orcid":false,"given":"Millie S.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9033-819X","authenticated-orcid":false,"given":"Kavitha J.","family":"Ramchandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohana","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Diehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel J.","family":"Myall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"48","key":"10.1016\/j.lungcan.2025.108747_b0005","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108747_b0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J. Natl Cancer Inst."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108747_b0015","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108747_b0020","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108747_b0025","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108747_b0030","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for Stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO), joint guideline update","volume":"39","author":"Hanna","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108747_b0035","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108747_b0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108747_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.04.010","article-title":"Overall survival in EGFR-mutant advanced non-small cell lung cancer treated with first-line osimertinib: a cohort study integrating clinical and biomarker data in the United States","author":"Sabari","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108747_b0050","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108747_b0055","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V.7.2024. National Comprehensive Cancer Network, Inc 2024."},{"key":"10.1016\/j.lungcan.2025.108747_b0060","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3_suppl","key":"10.1016\/j.lungcan.2025.108747_b0065","article-title":"First-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes","volume":"9","author":"Valdiviezo","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108747_b0070","doi-asserted-by":"crossref","first-page":"(3)","DOI":"10.1016\/S1556-0864(25)00199-6","article-title":"Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: final overall survival (OS) from the phase III MARIPOSA study","volume":"20","author":"Yang","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108747_b0075","article-title":"Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer","author":"AstraZeneca","year":"2025","journal-title":"In"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108747_b0080","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jtho.2018.10.150","article-title":"Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced NSCLC","volume":"14","author":"Kim","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108747_b0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.lungcan.2017.01.011","article-title":"Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes","volume":"106","author":"VanderLaan","year":"2017","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2025.108747_b0090","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-16-0966","article-title":"Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors","volume":"23","author":"Canale","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.lungcan.2025.108747_b0095","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","article-title":"Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance","volume":"24","author":"Yu","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.lungcan.2025.108747_b0100","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1158\/1078-0432.CCR-13-2391","article-title":"Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer","volume":"20","author":"Molina-Vila","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.lungcan.2025.108747_b0105","doi-asserted-by":"crossref","first-page":"12783","DOI":"10.18632\/oncotarget.3727","article-title":"Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma","volume":"6","author":"Bria","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108747_b0110","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jtho.2022.02.011","article-title":"Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma","volume":"17","author":"Vokes","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108747_b0115","doi-asserted-by":"crossref","unstructured":"23. Felip, E.; Cho, B. C.; Gutierrez, V.; Alip, A.; Besse, B.; Lu, S.; Spira, A. I.; Girard, N.; Califano, R.; Gadgeel, S. M.; Yang, J.; Nogami, N.; Azuma, K.; Curtin, J. C.; Zhang, J.; Panchal, A.; Ennis, M.; Sethi, S. N.; Bauml, J. M.; Lee, S. H. In Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study, ASCO Annual Meeting, Chicago, IL, 2024; Chicago, IL, 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.8504"},{"key":"10.1016\/j.lungcan.2025.108747_b0120","series-title":"In FLAURA2: Resistance, and impact of baseline TP53 alterations in patients treated with 1L osimertinib \u00b1 platinum-pemetrexed, World Conference on Lung Cancer, San Diego, CA, 2024","author":"Yang","year":"2024"},{"key":"10.1016\/j.lungcan.2025.108747_b0125","unstructured":"Stanford Actionable Mutation Panel for Solid Tumors (STAMP). https:\/\/stanfordlab.com\/content\/stanfordlab\/en\/test-details\/s\/STAMPT.html."},{"key":"10.1016\/j.lungcan.2025.108747_b0130","unstructured":"SNAPSHOT Cancer Genotyping (NGS). https:\/\/www.massgeneral.org\/pathology\/services\/center-for-integrated-diagnostics."},{"key":"10.1016\/j.lungcan.2025.108747_b0135","unstructured":"FoundationOne CDx. https:\/\/www.foundationmedicine.com\/test\/foundationone-cdx."},{"key":"10.1016\/j.lungcan.2025.108747_b0140","unstructured":"Tempus xT and xR. https:\/\/www.tempus.com\/oncology\/genomic-profiling\/xt-xr\/?srsltid=AfmBOop8-SJc5RgLC2NZIKOJCMP91E6HlzpomZU09j5TpWa7WNOGX7Jk."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108747_b0145","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jmoldx.2021.08.005","article-title":"Development and validation of StrataNGS, a multiplex PCR, semiconductor sequencing-based comprehensive genomic profiling test","volume":"23","author":"Tomlins","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.lungcan.2025.108747_b0150","unstructured":"UCSF 500 Cancer Gene Panel Test (UCSF500 \/ UC500). https:\/\/genomics.ucsf.edu\/UCSF500."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108747_b0155","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ng.3990","article-title":"Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers","volume":"49","author":"Blakely","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2025.108747_b0160","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/, 2021."},{"key":"10.1016\/j.lungcan.2025.108747_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.05.541","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","author":"Felip","year":"2024","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108747_b0170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cllc.2021.09.004","article-title":"Impact of tumor suppressor gene co-mutations on differential response to EGFR TKI therapy in EGFR L858R and Exon 19 deletion lung cancer","volume":"23","author":"Hellyer","year":"2022","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108747_b0175","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jtho.2023.10.001","article-title":"Co-occurring alterations in multiple tumor suppressor genes are associated with worse outcomes in patients with EGFR-mutant lung cancer","volume":"19","author":"Stockhammer","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108747_b0180","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40793-x","article-title":"Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis","volume":"14","author":"Skakodub","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108747_b0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/JTO.0b013e3182781e35","article-title":"Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors","volume":"8","author":"Kobayashi","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108747_b0190","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","article-title":"Effectiveness of tyrosine kinase inhibitors on \u201cuncommon\u201d epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer","volume":"17","author":"Wu","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108747_b0195","doi-asserted-by":"crossref","first-page":"11815","DOI":"10.1038\/ncomms11815","article-title":"Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients","volume":"7","author":"Chabon","year":"2016","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.lungcan.2025.108747_b0200","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-1542","article-title":"Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC","volume":"24","author":"Le","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108747_b0205","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108747_b0210","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108747_b0215","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108747_b0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/cancers11030341","article-title":"The presence of concomitant mutations affects the activity of EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC) patients","volume":"11","author":"Rachiglio","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2025.108747_b0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2017.06.014","article-title":"Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)","volume":"111","author":"Labbe","year":"2017","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108747_b0230","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001883","article-title":"Tumor suppressive functions of p53","volume":"1","author":"Zilfou","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.lungcan.2025.108747_b0235","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8, (1)","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108747_b0240","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108747_b0245","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.21037\/tlcr-20-141","article-title":"PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy","volume":"9","author":"Fang","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108747_b0250","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1038\/bjc.2014.210","article-title":"Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts","volume":"110","author":"Li","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108747_b0255","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1097\/JTO.0000000000000671","article-title":"Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas","volume":"10","author":"Eng","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108747_b0260","doi-asserted-by":"crossref","first-page":"35249","DOI":"10.1038\/srep35249","article-title":"The role of PIK3CA mutations among lung adenocarcinoma patients with primary and acquired resistance to EGFR tyrosine kinase inhibition","volume":"6","author":"Wu","year":"2016","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108747_b0265","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/s41388-019-1104-z","article-title":"Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation","volume":"39","author":"Jin","year":"2020","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108747_b0270","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bcp.2014.05.011","article-title":"Targeting PI3K\/AKT\/mTOR pathway in non small cell lung cancer","volume":"90","author":"Fumarola","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108747_b0275","first-page":"3233","article-title":"Prognostic value of KRAS\/TP53\/PIK3CA in non-small cell lung cancer","volume":"17","author":"Zhao","year":"2019","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108747_b0280","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4048\/jbc.2023.26.e30","article-title":"Concomitant PIK3CA and TP53 mutations in breast cancer: an analysis of clinicopathologic and mutational features, neoadjuvant therapeutic response, and prognosis","volume":"26","author":"Lin","year":"2023","journal-title":"J. Breast Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108747_b0285","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00432-019-02873-8","article-title":"Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer","volume":"145","author":"Chen","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108747_b0290","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12885-023-10674-z","article-title":"Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers","volume":"23","author":"Xie","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2025.108747_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107282","article-title":"Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer","volume":"182","author":"Lin","year":"2023","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108747_b0300","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.lungcan.2025.108747_b0305","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16142589","article-title":"Post-progression analysis of EGFR-mutant NSCLC following Osimertinib therapy in real-world settings","volume":"16","author":"Attili","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:03:16Z","timestamp":1759539796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":61,"alternative-id":["S0169500225006397"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108747","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108747"}}